Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of www tripeptide in preparing medicine for treating Alzheimer's disease

A technology for Alzheimer's disease and drugs, applied in the field of medicine, can solve the problems of large drug side effects, ineffective effects, unclear drugs for Alzheimer's disease, etc.

Inactive Publication Date: 2016-06-15
SUN YAT SEN UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the defects in the prior art that the drug for treating Alzheimer's disease is not clear, the effect is not obvious, and the drug has large side effects, the purpose of the present invention is to provide a drug for preventing and treating Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of www tripeptide in preparing medicine for treating Alzheimer's disease
  • Use of www tripeptide in preparing medicine for treating Alzheimer's disease
  • Use of www tripeptide in preparing medicine for treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0020] Experimental example 1, a kind of Thioflavin T test of WWW tripeptide for preventing or treating Alzheimer's disease:

[0021] Aβ 1-42 Dissolve in pH7.4, the concentration is 0.01mol / L in the phosphate buffer solution of 0.01mol / L and make 50μmol / L mixed solution, Aβ in this mixed solution 1-42 The initial concentration of the peptide was 50 μmol / L, and until the final concentration was 2.5 μmol / L, it was incubated at 37°C for 48 hours, and then ThT (5 μmol / L dissolved in 50 mmol / L glycine-NaOH solution, pH 8.50) was added for detection Fluorescence at 450nm and 485nm. Each sample was measured 3 times and the fluorescence intensity was recorded.

[0022] combine figure 1 As shown, the results of Example 1 show that: Thioflavin T can rapidly interact with Aβ 1-42 Combined with the polymer fiber, a new light with a wavelength of 450nm is excited, and the light with a wavelength of 482nm is obviously enhanced, while WWW tripeptide and Aβ 1-42 Co-cultured WWW tripeptid...

experiment example 2

[0023]Experimental example 2, a circular dichroism test of WWW tripeptide for preventing or treating Alzheimer's disease:

[0024] Aβ at a concentration of 50 μmol / L 1-42 Dissolve in phosphate buffer solution, and add WWW tripeptide with a concentration of 50μmol / L to the experimental group, then place it at 37°C and incubate for 48h, the Aβ in the mixed solution 1-42 and the final concentration of WWW tripeptide is 5μmol / L, using a container dish with a thickness of 1mm, Aβ 1-42 Monomeric and WWW tripeptide-Aβ 1-42 The complex samples were respectively prevented from detecting the structure in a circular dichroism spectrometer, and the spectra were recorded at 25°C, with a wavelength of 190-260nm and a wave width of 0.5nm.

[0025] combine figure 2 As shown, the results of Example 2 show that the circular dichroism spectrum shows that the β sheet structure in the WWW tripeptide-Aβ complex will decrease, such as figure 2 As shown, circular dichroism detection of Aβ 1-42...

experiment example 3

[0026] Experimental Example 3, a transmission electron microscope (TEM) test of a WWW tripeptide for preventing or treating Alzheimer's disease:

[0027] Aβ with phosphate buffer (PBS, pH7.4) 1-42 The sample was dissolved to a concentration of 1 mg / ml, and then placed in the WWW tripeptide experimental group and the blank control group at a concentration of 25 μmol / L until the final concentration of the mixed solution was 25 μmol / L. 300 wells of Formvar-carbon copper grid, stained with 1% uranyl formate for 1 min, dried in the air, and observed under an electron microscope to detect Aβ 1-42 and WWW Tripeptide-Aβ 1-42 The structure of the complex.

[0028] combine image 3 Shown, embodiment 3 result shows: as image 3 As shown in the electron microscope image, from Aβ 1-42 Monomer, high-density long linear Aβ can be observed in the figure 1-42 fibers, the fibers aggregate into parallel bundles, and the bundles cross each other; however, from WWW tripeptide-Aβ 1-42 Only a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention claims the use of WWW tripeptide in the preparation of drugs for preventing or treating Alzheimer's disease, which belongs to the field of medicine. The WWW tripeptide of the present invention has a clear dosage for animals, and can be made into tablets, microspheres, powders, oral liquids, and injections. When the WWW tripeptide is used for the treatment of Alzheimer's disease, it can be used alone or as a drug. It can be used in combination with other Alzheimer's disease drugs with different mechanisms of action. When the pharmaceutical composition composed of WWW tripeptide, tetrandrine and triptolide is used for the treatment of Alzheimer's disease, it can not only reduce the Toxic and side effects, and can achieve the effect of synergistic treatment, pharmacological experiments have confirmed that WWW tripeptide can effectively inhibit Aβ 1-42 Aggregates and prevents Aβ 1-42 The phenomenon of oligomerization of monomers can significantly inhibit the deposition of β-amyloid protein, and it has a definite curative effect for the prevention or treatment of Alzheimer's disease and few side effects, so it has broad medical application prospects.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a new application of a known drug, in particular to the application of WWW tripeptide in the preparation of drugs for treating Alzheimer's disease. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized by short-term memory loss, persistent cognitive decline, and behavioral disturbances. Alzheimer's disease affects a huge number of people around the world, bringing great suffering to people's lives. Now, the exact pathogenesis of AD is still unclear, and it is preliminarily believed to be the joint result of aging, genetic and environmental factors. At present, there are many theories to confirm the exact pathogenesis of AD, among which the most widely accepted amyloid hypothesis is the amyloid hypothesis based on the aggregated and fibril-forming β-amyloid (Aβ) peptide as a biomarker. Aβ is a short peptide consisting of 38 to 42 amino acid resi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/06A61P25/28A61K31/585A61K31/4748
Inventor 顾怀宇段松伟黄嘉琦林润轩林睿邦凌楚雯
Owner SUN YAT SEN UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More